Severe cutaneous interface drug eruption associated with bendamustine

Dermatology Online Journal

Volumn 16, Issue 7, 2010, Pages

  Alamdari, Habibollah S ^a   Pinter Brown, Lauren ^a   Cassarino, David S ^b   Chiu, Melvin W ^a,c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b KAISER PERMANENTE MEDICAL CENTER   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALLOPURINOL; BENDAMUSTINE; CYCLOPHOSPHAMIDE; DOCUSATE SODIUM; FLUDARABINE; LORATADINE; PARACETAMOL; PREDNISONE; RITUXIMAB; VALSARTAN; VINCRISTINE;

ADVERSE OUTCOME; AGED; ALLERGIC RHINITIS; ARTICLE; B CELL LYMPHOMA; CANCER COMBINATION CHEMOTHERAPY; CANCER GRADING; CANCER RADIOTHERAPY; CASE REPORT; CLINICAL FEATURE; CONSTIPATION; DISEASE SEVERITY; DOSE RESPONSE; DRUG DOSE REDUCTION; DRUG ERUPTION; DRUG WITHDRAWAL; ERYTHEMA; HAND RASH; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; HYPERTENSION; LYMPHOCYTIC INFILTRATION; MACULOPAPULAR RASH; MALE; MOUTH LESION; OSTEOARTHRITIS; PUNCH BIOPSY; SKIN DEFECT; SKIN EXFOLIATION; TREATMENT DURATION;

EID: 77958146947     PISSN: None     EISSN: 10872108     Source Type: Journal    
DOI: None     Document Type: Article

References (12)

1. Treanda [package insert]. Frazer, PA: Cephalon, Inc.; 2008.
2. Knauf WU, Lissichkov T, Aldaoud A, et al. Phase III randomized study of bendamustine compared with chlorambucil in previously untreated patients with chronic lymphocytic leukemia. J Clin Oncol 2009; 27:4378-4384. [PubMed]
3. Friedberg JW, Cohen P, Chen L, et al. Bendamustine in patients with rituximab-refractory indolent and transformed non-Hodgkin's lymphoma: Results from a phase II multicenter, single-agent study. J Clin Oncol. 2008; 26:204-210. [PubMed]
4. Roujeau JC, Stern RS. Severe adverse cutaneous reactions to drugs. N Engl J Med 1994; 331:1272. [PubMed]
5. Stern RS, Shear NH. Cutaneous reactions to drugs and biological modifiers. In: Arndt KA, LeBoit PE, Robinson JK, Wintroub BU, eds, Cutaneous Medicine and Surgery: An Integrated Program in Dermatology. 1st ed. Philadelphia, PA: WB Saunders; 1996: 412.
6. Habif TP. Drug Eruptions: Clinical Patterns and Most Frequently Causal Drugs. In: Habif TP. Clinical Dermatology: A Color Guide to Diagnosis and Therapy. 4th ed. Philadelphia, PA: Mosby; 2004: Chapter 14.
7. Bigby M. Rates of cutaneous reactions to drugs. Arch Dermatol. 2001; 137:765-770. [PubMed]
8. Gerson D, Sriganeshan V, Alexis JB. Cutaneous drug eruptions: a 5-year experience. J Am Acad Dermatol. 2008; 59:995-999. [PubMed]
9. Crowson AN, Brown TJ, Magro CM. Progress in the understanding of the pathology and pathogenesis of cutaneous drug eruptions. Am J Clin Dermatol. 2003; 4:407-428. [PubMed]
10. Crowson AN, Magro CM, Mihm MC. Interface dermatitis. Arch Pathol Lab Med. 2008; 132:652-666. [PubMed]
11. Brönnimann M, Yawalkar N. Histopathology of drug-induced exanthems: is there a role in diagnosis of drug allergy? Curr Opin Allergy Clin Immunol. 2005; 5:317-21. [PubMed]
12. Sanborn RE. Cutaneous reactions to chemotherapy: commonly seen, less described, little understood. Dermatol Clin. 2008; 26:103-119. [PubMed]